Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Adicet Bio ( (ACET) ).
On January 7, 2026, Adicet Bio reported that enrollment in its Phase 1 prulacabtagene leucel (prula-cel) program in autoimmune diseases had more than doubled since October to over 20 patients as of December 31, 2025, with all seven autoimmune cohorts now actively enrolling and the first ANCA-associated vasculitis patient dosed. The company has secured U.S. FDA alignment to allow outpatient dosing of lupus nephritis and systemic lupus erythematosus patients in ongoing and future trials, is running a Phase 1 study in treatment-refractory rheumatoid arthritis to test reduced conditioning regimens, and plans multiple clinical data updates through 2026 as it works toward a pivotal trial design. Adicet is also progressing preclinical development of ADI-212 for metastatic castration-resistant prostate cancer, targeting a regulatory filing in the first half of 2026, while an October 2025 equity raise of about $74.8 million has extended its cash runway into the second half of 2027, underpinning its ability to execute on these clinical and regulatory milestones.
The most recent analyst rating on (ACET) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Adicet Bio stock, see the ACET Stock Forecast page.
Spark’s Take on ACET Stock
According to Spark, TipRanks’ AI Analyst, ACET is a Neutral.
The score is held down primarily by weak financial performance (no revenue, large losses, and significant cash burn with shrinking equity) and bearish technicals (below key moving averages with negative MACD). Corporate events are mixed—encouraging Phase 1 results help, but Nasdaq compliance risk offsets—while valuation is difficult to assess given negative earnings and no dividend yield.
To see Spark’s full report on ACET stock, click here.
More about Adicet Bio
Adicet Bio, Inc., based in Redwood City, Calif., is a clinical-stage biotechnology company focused on discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company is advancing an “off-the-shelf” pipeline of chimeric antigen receptor (CAR)-engineered gamma delta T cells, including its lead candidate prulacabtagene leucel (prula-cel) for autoimmune indications and ADI-212 for solid tumors such as metastatic castration-resistant prostate cancer.
Average Trading Volume: 164,212
Technical Sentiment Signal: Sell
Current Market Cap: $78.06M
Find detailed analytics on ACET stock on TipRanks’ Stock Analysis page.